Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy☆
References (63)
- et al.
Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects
Metabolism
(1992) - et al.
Plasminogen activator in plasma: Risk factor for recurrent myocardial infarction
Lancet
(1987) - et al.
Acanthosis nigricans and obesity: Acquired and intrinsic defects in insulin action
Metabolism
(1986) - et al.
Effect of androgen excess on inappropriate gonadotropin secretion as found in the polycystic ovary syndrome
Am J Obstet Gynecol
(1982) Polycystic ovary syndrome and the androgen-insulin connection
Am J Obstet Gynecol
(1991)- et al.
The influence of androgens on insulin resistance
Fertil Steril
(1984) - et al.
Hyperinsulinemia in hyperthecosis of the ovaries
Am J Obstet Gynecol
(1986) - et al.
Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion
Fertil Steril
(1986) Quantitative estimation of protein by electrophoresis in agarose gel containing antibodies
Ann Biochem
(1966)- et al.
The relationship of insulin to sex hormone-binding globulin: Role of obesity
Fertil Steril
(1989)
Clinical signs of androgen excess risk factors for coronary artery disease
Fertil Steril
(1990)
Insulin as an effector of human ovarian and adrenal steroid metabolism
Endocrinol Metab Clin North Am
(1991)
Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
Diabetologia
(1980)
Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during follow-up of the Helsinki policemen study population
Acta Med Scand
(1985)
Hyperinsulinemia, sex, and risk of atherosclerotic vascular disease
Circulation
(1991)
The role of hyperinsulinemia in the development of lipid disturbances in non-obese and obese women with the polycystic ovary syndrome
J Endocrinol Invest
(1991)
Evidence for an independent relationship between insulin resistance and fasting plasma HDL cholesterol, triglyceride and insulin concentrations
J Intern Med
(1992)
Role of insulin resistance in human disease
Diabetes
(1988)
Lipid metabolism in women with polycystic ovary syndrome: Possible implications for an increased risk of coronary heart disease
Fertil Steril
(1984)
Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
J Clin Endocrinol Metab
(1985)
Insulin resistance in essential hypertension
N Engl J Med
(1987)
Polycystic ovary syndrome: Lack of hypertension despite profound insulin resistance
J Clin Endocrinol Metab
(1992)
Hypertension as a disease of carbohydrate and lipoprotein metabolism
Am J Med
(1989)
Role of abnormalities of carbohydrate and lipoprotein metabolism in the pathogenesis and clinical course of hypertension
J Cardovasc Pharmacol
(1990)
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors
J Intern Med
(1991)
Plasminogen activator inhibitor-1 and insulin levels in various insulin resistance states
Diabetes Metab
(1992)
Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
J Clin Endocrinol Metab
(1980)
Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
Diabetes
(1989)
Polycystic ovary syndrome
Compr Ther
(1990)
Polycystic ovary syndrome: A changing perspective
Clin Endocrinol
(1989)
Cited by (818)
Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling
2023, Biomedicine and PharmacotherapyThe polycystic ovary syndrome: the first 150 years of study
2023, F and S ReportsCXCL13 and CXCR5 are upregulated in PCOS mice ovaries but downregulated following metformin administration
2022, Molecular and Cellular EndocrinologyMetformin: Is it a drug for all reasons and diseases?
2022, Metabolism: Clinical and Experimental
- ☆
Supported in part by Grant No. M-392-91, Merida, Venezuela, M-402, and by Grants No. 757 and 2–728 from the Jewish Hospital Medical Research Council, Jewish Hospital of Cincinnati.
Copyright © 1994 Published by Elsevier Inc.